Lexicon Pharmaceuticals Inc. (LXRX)
NASDAQ: LXRXHealth CareBiotechnology: Pharmaceutical PreparationsUSD
At close: Nov 20, 4:00 PM ET · Delayed 15 min
LXRX stock chart
Technical analysisKey statistics
All statistics- Market cap
- $681.21M
- EPS (TTM)
- -$0.15
- Dividend yield
- None
- 52-week range
- 1.10 – 2.68
- Day range
- 1.47 – 1.70
- Volume / Avg
- 4.20M / 2.56M
- Beta
- —
- Shares outstanding
- 445.23M
52-week range
LXRX stock today
Shares of Lexicon Pharmaceuticals (LXRX) finished lower on Nov 20 at $1.53, a drop of 8.38% or $0.14 per share, versus the S&P 500's 3.70% decline. At this level, LXRX sits in the middle of its 52-week range of $1.10 to $2.68: 42.9% below the high, set on Jun 30, 2026 and 39.1% above the low. LXRX is up 33.0% year to date, outperforming the S&P 500 (+1.2%). Over the past 12 months, the stock has gained 14.2%.
Lexicon Pharmaceuticals has posted a net loss over the last twelve months (EPS of -$0.15), so its P/E ratio is not meaningful.
Summary generated from market data by MetaCap's automated system. Methodology
About Lexicon Pharmaceuticals
Company profileLexicon Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the discovery, development, and commercialization of pharmaceutical products for the treatment of human disease. The company develops sotagliflozin, an orally-delivered small molecule drug for the treatment of hypertrophic cardiomyopathy, and ZYNQUISTA (sotagliflozin) for the treatment of type 1 diabetes. It also commercializes INPEFA (sotagliflozin), a once-daily oral tablet to reduce the risk of cardiovascular death, hospitalization for heart failure, and urgent heart failure visit in adults with heart failure or type 2 diabetes, CKD, and other cardiovascular risk factors.
- Sector
- Health Care
- Industry
- Biotechnology: Pharmaceutical Preparations
- CEO
- Dr. Michael S. Exton Ph.D.
- Headquarters
- The Woodlands, TX
- Employees
- 81
- Website
- lexpharma.com
Financial highlights
Full financialsIn fiscal 2025, Lexicon Pharmaceuticals generated $49.8 million in revenue, up 60.2% from fiscal 2024, its 3rd consecutive year of revenue growth. Lexicon Pharmaceuticals reported a net loss of $50.3 million, compared with a loss of $200.4 million a year earlier. Gross margin was 99.4% (up from 98.0%) and operating margin -98.2%.
| Fiscal year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|
| Revenue | $49.80M | $31.08M | $1.20M | $139.00K | $298.00K |
| Growth | +60.24% | +2481.48% | +766.19% | -53.36% | -98.76% |
| Net income | $-50.34M | $-200.40M | $-177.12M | $-101.94M | $-87.76M |
| EPS (diluted) | $-0.14 | $-0.63 | $-0.80 | $-0.62 | $-0.60 |
Analyst forecast
ForecastConsensus (6 analysts)
buy
Avg. price target
$4.52+195.42%
- Strong buy 1
- Buy 3
- Hold 2
- Sell 0
- Strong sell 0
Target range
Ratings and targets reflect third-party analyst opinions, not MetaCap recommendations.
Earnings
Earnings history- Last reported (Sep/2026)
- Nov 5, 2026
- EPS actual vs est.
- $-0.03 vs $-0.06
- Surprise
- +50.00%
LXRX news
All LXRX news- Lexicon Pharmaceuticals to Present at the Jefferies Global Healthcare Conference in LondonGlobeNewswire
- Lexicon Pharmaceuticals (LXRX) Reports Q3 Loss, Tops Revenue EstimatesNasdaqLXRX, TGTX
- Lexicon Pharmaceuticals GAAP EPS of -$0.03 beats by $0.03, revenue of $11.3M beats by $7.16MSeeking Alpha
- Lexicon Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Clinical UpdatesGlobeNewswire
- Lexicon Pharmaceuticals Q3 2026 Earnings PreviewSeeking Alpha
- Lexicon Pharmaceuticals to Report Third Quarter 2026 Financial Results on November 5, 2026GlobeNewswire
- Lexicon Pharmaceuticals Provides Update on Baseline Patient Characteristics for Pivotal Phase 3 SONATA-HCM Study of Sotagliflozin in Symptomatic Hypertrophic CardiomyopathyGlobeNewswire
- Lexicon Pharmaceuticals Announces Publication of New Research Highlighting Sotagliflozin’s Biological Effects in Cardiovascular DiseaseGlobeNewswire
Lexicon Pharmaceuticals peers
Health Care sector| Company | Price | % Chg | Market cap | Compare |
|---|---|---|---|---|
| APMDApnimed Inc. | 16.09 | -6.70% | $669.84M | vs LXRX |
| NVCTNuvectis Pharma Inc. | 19.39 | -2.27% | $666.80M | vs LXRX |
| SGMTSagimet Biosciences Inc. Series A | 9.08 | -5.61% | $648.02M | vs LXRX |
| KURAKura Oncology Inc. | 6.91 | -5.99% | $634.88M | vs LXRX |
| OBXObsidian Therapeutics Inc. | 12.00 | -1.23% | $741.29M | vs LXRX |
| JANXJanux Therapeutics Inc. | 10.08 | -2.04% | $616.73M | vs LXRX |
| ABUSArbutus Biopharma Corporation | 4.02 | -1.23% | $616.24M | vs LXRX |
| OLMAOlema Oncology Inc. | 7.02 | -1.82% | $615.00M | vs LXRX |
Indexes, lists and sector
Lexicon Pharmaceuticals stock FAQ
What is Lexicon Pharmaceuticals's stock price today?
LXRX last traded at $1.53 as of Nov 20, 4:00 PM EST, down 8.38% on the day. Prices are delayed at least 15 minutes.
Does Lexicon Pharmaceuticals pay a dividend?
No. Lexicon Pharmaceuticals does not currently pay a regular cash dividend.
Who is Lexicon Pharmaceuticals's CEO?
Dr. Michael S. Exton Ph.D. is the chief executive officer of Lexicon Pharmaceuticals Inc., which has about 81 employees.
Has LXRX ever split its stock?
Yes. The most recent LXRX stock split was a 1-for-7 split on May 21, 2015.
What is the LXRX 52-week high?
The 52-week high for LXRX is $2.68 and the 52-week low is $1.10. The stock is currently 42.9% below its high.